P. Kent Hawryluk

President & CEO

P. Kent Hawryluk (President & CEO) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in MBX. Across 1 priced purchase filing, the average 21-session return was +18.0% from execution and +8.7% from disclosure (delay-adjusted; derived). The largest single filing was $526K of MBX (18,500 sh × $28.41, as filed), executed Mar 13. Data as of Nov 8 2026.

Add to watchlist

Return, ttmiAverage return per filing, trailing twelve months

+18.0%

avg across 1 priced filings

Delay-adjustediThe same average, entered at disclosure dates

+8.7%

same 1 filings, from disclosure

Filings, ttm

1 buys · 0 sells

Median delay

execution → disclosure

Volume, ttmiDollar value disclosed in the trailing twelve months

$526K

shares × price, as filed

Last traded

Mar 13

Filed Mar 16

Open performance→

Volume by month

Buys $1.3M Sells $0

Shares × price, as filed · by filing month · past 24 months

Most traded names

MBX MBX 3 buys · 0 sells 3 filings

Recent filings

MBXPURCHASE MBX Biosciences, Inc. View filing → $526K
18,500 sh × $28.41
Exec Mar 13
Filed Mar 16 · 8:02 AM ET MBXPURCHASE MBX Biosciences, Inc. View filing → $273K
20,000 sh × $13.64
Exec Oct 20 2025
Filed Oct 21 2025 · 5:43 PM ET MBXPURCHASE MBX Biosciences, Inc. View filing → $534K
50,000 sh × $10.69
Exec Feb 4 2025
Filed Feb 5 2025 · 5:30 PM ET